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Diabetic nephropathy is becoming a major and growing cause
of endstage renal disease (ESRD) in all industrialized countries
[1, 21. In Europe, the number of patients with diabetic nephrop-
athy and ESRD that have been put on renal rcplacemcnt
therapy has increased rapidly during the last years. By the end
of 1980, diabetic patients accounted for 3% of all patients alive
and treated by a dialysis method or living with a functioning
graft [1]. As demonstrated by recent results [I, 3, 4—6] exclu-
sion of insulin-dependent diabetic (IDD) patients from renal
function replaccment therapy is no longer acceptable when
treatment facilities are available; therefore, time has come for a
critical appraisal of the results obtained with different dialysis
techniqucs in a diabetic population.
Continuous ambulatory peritoneal dialysis (CAPD), a valu-
able alternative to hemodialysis in treating ESRD 7—121 is
currently quoted as a satisfactory dialysis method for IDD
patients [5, 6, 13—17]. Recently very encouraging results ob-
served in 20 patients have been reported by Amair et al [18].
However, small scries and too brief follow-up periods have not
allowed valid comparisons between CAPD and other modes of
therapy in a diabetic population. In this study, we report our
experience with 24 IDD paticnts treated by CAPD over a 40-
month period.
Methods
A total of 90 IDD patients with ESRD have been treated
between January 1973 and December 1981 by dialysis methods
and/or kidney transplantation in Groupe Hospitalier Pitie Salpe-
triere. Twenty-four of them have been on CAPD since August
1978, CAPD was the first choice treatmcnt in 20 patients; four
were transferred from hemodialysis because of ocular (one
patient) or cardiovascular complications (three patients). As of
December 1981, the cumulative duration of CAPD treatment
was 256 patient months. The average time on CAPD was 10.6
months (range, 2 to 32 months). Eleven patients were on CAPD
for at least 12 months and five for more than 18 months.
At the beginning of treatment there were 14 males and 10
females whose mean age was 54.7 years (range, 28 to 71). The
mean duration of diabetes was 23.2 9.5 years, and mean
residual creatinine clearance was 5.7 1.3 mI/mm. All patients
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had severe extrarenal complications that are summarized in
Table 1. Two patients were totally blind and six legally blind.
Walking impairment was present in 14 patients.
CAPD training was pci-formed in a separate unit with a
nursing staff especially devoted to this task. The training period
usually lasted 17 days (range, 12 to 28). CAPD was conducted
through a double cuff Tenckhoff catheter with a preferential use
of the curled type [19]. The composition of the dialysate and the
equipment used have been described previously [20]. At the
start of treatment all patients, but one who retained residual
creatinine clearance of 7 mI/mm, performed four exchanges per
day, using routinely three 2-liter bags with a 1 .5% dextrose
concentration during the day time and one 2-liter bag with a
4.5% dextrose concentration overnight. Since October 1981,
two legally blind patients performed continuous cyclic peritone-
al dialysis (CCPD) with the help of their relatives, using a
"cycler" dispensing 2-liter bags three times overnight while 2
liters of 4.5% dextrose dialysis fluid was left in the peritoneal
cavity during the day time.
Considering the daily peritoneal absorption of about 100 g of
dextrose and the daily loss of about 10 g of protein through the
dialysate effluent, the patients were asked to eat a diet with a
carbohydrate content, ranging between 130 and 150 g/day and a
protein content of about 1.5 g/kg of body weight/day. The water
and salt intake were adjusted according to the residual renal
function, clinical state of hydration, and blood pressure values.
Furosemide, 500 mg/day, was administered orally in 18 patients
with the aim of preserving residual urinary output.
Patients and their relatives were trained to measure the blood
sugar level with a reflectance meter (Ames "Dextrometer").
During the initial training control period blood sugar was
measured routinely four times a day before changing the bag
plus occasionally 2 hr after meals. At home two such readings
were performed daily, one during fasting before changing the
bag in the morning and the second in the late afternoon before
supper. Once a month a series of six readings were obtained.
They were performed before changing the bags and 2 hr after
lunch and supper. In 18 out of 24 patients, regular insulin was
injected into the connecting tube after the drainage of a bag and
immediately before installation of the following one. On the
average, 15 to 20 units of insulin were needed with the 1.5%
dextrose concentration bags and 30 to 40 U with the 4.5%
dextrose concentration. The dose of insulin administered
through the catheter was increased or decreased by 2 to 4 U
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Table 1. Extrarenal complications in 24 IDD patients at the start of
CAPD treatment
Complications
Patients
N %
Hypertension, 16OI95 mm Hg 22a 92
Retinopathy 24 100
Clinical peripheral neuropathy 20 83
Previous history of myocardial
infarction 11 46
Angina pectoris 16 66
Peripheral vascular disease 16 66
Enteropathy 3 12
a Two patients transferred from HD were normotensive.
according to the blood sugar levels measured the previous day.
Insulin requirements were determined to avoid 2 hr postprandi-
al sugar levels over 11 mmoles/liter.
Results
Main clinical and biological parameters. Results obtained in
11 IDD patients treated by CAPD for at least 1 year are
summarized in Table 2.
After an initial drop of body weight in relation with the
correction of overhydration, a trend to gain weight was routine-
ly observed but remained moderate. Cure of hypertension was
obtained in most patients and only three patients (27%) were
still receiving antihypertensive drugs after 1 year on CAPD.
Several hypotensive episodes were observed in seven patients.
Neither peritoneal nor residual renal creatinine clearances
deteriorated during the priod of observation. Furosemide was
administered routinely to 9 out of 11 patients followed for at
least 1 year.
A sharp increase of the heinatocrit level was observed after
treatment began. The value stabilized after 6 months to about
33%; the amount of transfused blood was less than 0.1 packed
cell unit per patient month. No deterioration of hematocrit was
observed in the five patients undergoing their second year of
treatment. Major serum electrolytes remained within the nor-
mal range. A sharp decrease of phosphorus levels occurred
early after starting treatment and at 1 year only 1 of the 11
patients used phosphate binders. Total serum protein and
serum albumin were stabilized after 6 months within the lower
normal range whereas cholesterol and triglycerides were elevat-
ed moderately throughout the observation period. There was no
statistical difference between the biological values observed on
the 3rd and the 12th months.
Control of diabetes. One acute hypoglycemic episode was
observed in two patients receiving beta-blockers as antihyper-
tensive drugs. After the adjustment of each patient's personal
needs the mean daily doses of insulin were not modified
significantly over the period of observation. The daily dose of
insulin administered intraperitoneally was between 60 and 130
U. The insulin requirements increased during peritonitis epi-
sodes. Fasting blood glucose levels decreased during treatment
with CAPD. The mean values at 1 year in nine patients using
intraperitoneal administration of insulin were 5.8 0.7 mmoles/
liter (Fig. 1). The mean serum glycosylated hemoglobin (HbA1)
in 11 patients dialyzed for at least a year did not change
significantly: 10.3 2.0% at start of treatment and 9.6 1.4%
at 1 year. (Mean values in nondiabetics were 8.6 1.2 when
treated by CAPD and 6.4 0.8% when hemodialyzed).
Visual status. Sight was assessed in 15 patients treated for at
least 6 months. The evolution is summarized in Table 3. An
improvement was observed in two patients while aggravation
was observed in three. The deterioration was due in two of
these three patients to the extension of proliferative retinopathy
and in another to severe intravitreous hemorrhage favored by
poor control of blood pressure. Laser treatment allowed a good
recovery of vision of one eye in one patient.
Peripheral vascular disease. Despite severe clinical peripher-
al vascular lesions present in 66% of the patients when starting
CAPD treatment, only three amputations, two of a lower limb
and one of toes, were required during the period of observation.
Neurological status. Clinical evolution is summarized in
Table 4. In most patients nerve conduction velocity values
when measurable remained stable. Of the 14 patients unable to
walk initially, seven improved, three deteriorated, and four
remained stable.
Causes of drop out and technical complications. The actuar-
ial survival rates were 84% at 1 year and 72% at 18 months. The
rates of continuation of dialysis were 75 and 60% during the
same period (Fig. 2). Causes of drop out were deaths in six
patients and transfers to HD in three other patients. Two
patients died of a vascular accident, one of myocardial infarc-
tion, and the other of stroke. Other causes of death were
peritonitis from bowel perforation in one patient, cachexia in
one patient, lower limb amputation and sepsis in two patients.
Three patients were transferred to hemodialysis because of
chronic malnutrition associated with a decrease of ultrafiltra-
tion and a consecutive overhydration in two patients and
abdominal surgery after a ruptured diverticulum in another one.
Two patients died from persisting malnutrition and cachexia
within 3 months following their transfer to HD.
The overall incidence of peritonitis was 22 episodes in 256
patient months (one episode every 12.2 patient/months). Seven-
teen episodes yielded a pathogen: Staphylococcus was respon-
sible in nine episodes, (four Staphylococcus aureus, five Staph-
ylococcus epidermitis), Streptococcus in three, Acinetobacter
in two, Escherichia coli, Aspergillus, and Klebsiella pneumo-
niae each in one. Aseptic peritonitis was observed in five
episodes. Three of them occurred in patients who had been
receiving antibiotics prior to peritonitis for another reason. All
patients were hospitalized and treatment initiated with continu-
ous lavage using automatic equipment and intraperitoneal ad-
ministration of antibiotics. Fungal peritonitis was treated suc-
cessfully with the intraperitoneal administration of amphoteri-
cm B without removal of the catheter. Only two peritoneal
catheters had to be changed after a mean period of 6 months,
one because of recurrent peritonitis and one because of infec-
tion at the exit site.
If one excludes the single patient who was hospitalized 180
days for a perforated sigmoid diverticulum, the average dura-
tion of hospitalization was 13 days/year. The rehabilitation level
is difficult to evaluate in a diabetic population with many
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Table 2. Evolution of clinical and biological parameters in patients treated by CAPD for at least 12 months'
Normal range
3 6 9
extrarenal complications and a mean age of 54 years at the start
of treatment. Only four patients maintained a professional
occupation.
Discussion
As a larger experience with diabetic patients with ESRD has
been gained during the last 10 years. opinions on the treatment
of such patients with dialysis methods and kidney transplanta-
tion have changed [2, 211. Most centers currently accept
diabetic patients for either dialysis or transplantation. CAPD
over the past 3 years, both in Europe and North America, has
Months
Patients (N)
Weight, kg
0
(11)
63.7 9.5
3
(ii)
64.1 II
6
(1/)
65.2 9
12
(1])
18
(5)
65 10 68 3
Blood pressure, mm Jig
Systolic
Diastolic
210
126
28
17
170
96
24
12
166
92
29
13
148
80
27
11
162
89
22
12
Peritoneal creatinine clearance.
mi/mm — 5.2 0.8b 5.2 0.7h 4.9 0.6" 4.8 0.7
Residual renal creatinine
clearance, mi/mn 4.2 1.9 3.2 1.6" 3.3 1.1 3.1 0.7" 3.5 0.9
Hematocrit, % 26 6 31 4" 34 4 33 5" 36 3
Creatinine, imoles/l,ter 912 116 880 186" 690 170 720 140" 770 160
Urea, mmoles/liier 38.2 9.1 26.2 + 5" 24 4 22 7h 19 6
Bicarbonates, ,n,noies/Iiter 19.7 4 23.1 2" 24 1.9 25 3" 25 2
Potassium, mmoles/liter 5 0.6 4.1 0.3" 3.9 0.5 3.9 0.5" 4.2 0.3
Calcium, mmoles/Iiter 2.1 0.6 2.3 0.3" 2.4 0.2 2.4 0.2" 2.5 0.2
Phosphorus, mmoles/Iiter 2.3 0.5 1.5 0.4" 1.4 0.3 1.3 0.2" 1.4 0.1
Cholesterol, ,n,noles/liter 4.9 0.9 5.1 1" 5.8 1.2 5.8 1.1" 6.3 1.2
Triglycerides, mmoles/liter 1.3 0.8 2.2 0.8" 2.3 0.9 2.4 lb 2.3 0.8
Total proteins, g/iiter 64 3.6 62 5" 61 3 60 4h 61 5
Albumin, g/liter 34 2.9 33 4.2h 31 4 31 3" 32 4.6
All values are expressed as mean SD.
b The difference evaluated by Student's I test between the 3rd and 12th months was not statistically significant.
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Fig. 1. Evolution of mean flisting blood glucose levels in nine patients
treated by CAPD for at least a year with insulin instillation through the
peritoneal catheter.
3 18
Time, months
Fig. 2. Actuarial survival rate (upper curve) and maintenance on
continuous ambulatory peritoneal dialysis (lower curve). Numbers
indicate patients at risk.
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.Patients At start
of CAPD
Latest
.
examination
Totally blind 1 2
Legally blind
(VA 20/200) 4 4
Good VA of one eye,
(VA 20/200 to 40/40) 3 1
Good VA of both eyes 7 8
Abbreviation: VA, visual acuity.
been the first choice treatment for a rapidly increasing number
of diabetic patients [2, 3, 5, 7]. Nevertheless, because the
experience with this dialysis method is brief and with a small
number of patients, opinions regarding the most appropriate
method of treatment for IDD diabetic patients are still set
forward [2, 5, 6, 16, 17].
The rate of continuation on CAPD of our IDD patients was
75% at 1 year and 60% at 18 months. A rate as high as 87% at 1
year was recently reported in a diabetic population a little
younger than ours [18]. These results are superior to the 67%
overall mean survival at 1 year obtained in IDD patients on
maintenance hemodialysis in 14 centers as was recently re-
viewed [221. Similarly, they are either superior or similar to the
best results reported with center hemodialysis in patients of the
same age group [1, 23] or after cadaveric kidney transplantation
[24, 25]. The main causes of death in an IDD population treated
by CAPD are cardiovascular. Peritonitis may be fatal, especial-
ly when complicated with bowel perforation or it occurs in
cachetic patients or when it is due to fungi. Only three patients
were transferred to HD, a failure rate lower than that observed
in nondiabetic patients [7, 12].
The clinical status of most of our IDD patients treated by
CAPD can be judged as very good. Persistence of a relatively
high hematocrit value was a major contributing factor to the
well-being feeling of the patients. After an initial drop of body
weight, which reflects the correction of the predialysis overhy-
dration, a steady but moderate weight gain was recorded the
first year. Careful dietary control and adequate insulin manage-
ment might be required to avoid further increase in body
weight. Hypertension was controlled easily with either discon-
tinuation or reduction of antihypertensive drugs over time.
Postural hypotension was observed in some patients and was
mainly due to overuse of hypertonic dialysate and the resulting
hypovolemia.
The evolution of the major biological parameters studied in
this IDD population was quite satisfactory and the results were
similar to those observed in nondiabetic patients [7, 9, 12]. We
agree with others [9, 26—28] that the daily use of no more than
one 2-liter dialysate bag with 4.5 dextrose concentration may
prevent the hypertriglyceridemia frequently observed [7, 10, 11,
28] among these patients.
Loss of ultrafiltration through the peritoneum requiring over-
use of hypertonic solutions [27] with consecutive dietary and
metabolic disorders was not observed in this series and the
Months 0 6 12 18
Patients (N) (24) (15) (11) (5)
Walking impairment, N 14 8 3 1
Clinical improvement — 6 1 —
Clinical aggravation — 2 1 —
Abbreviation: N, with and without parentheses, refers to the number
of patients.
peritoneal creatinine clearance remained stable within the limits
of observation. The absence of further deterioration over time
of residual renal function was unexpected and differs from what
is routinely observed with either hemodialysis or intermittent
peritoneal dialysis [16] and from what was recently reported
among diabetic patients on CAPD [18]. The persistence of
residual renal function during the first 18 months of treatment
may be related to the stable high plasma osmolality, the absence
of acute fluid shifts, and the routine administration of
furosemide.
Stabilization or even improvement of the visual status of
diabetic patients has been reported among patients on CAPD
[17, 29, 30]. However, aggravation related to the extension of
proliferative retinopathy or vitreous hemorrhage can be ob-
served. Our data, in agreement with our experience with IDD
patients on hemodialysis [31], illustrates that most of the
irreversible visual lesions occur before starting dialysis, during
the terminal phase of renal failure, when poor control of blood
pressure and blood glucose are common. A better control of
these two parameters is essential, if severe ocular complica-
tions are to be avoided [32]. Partial or total blindness consti-
tutes the major limitation in the life of IDD dialyzed patients
and a real handicap for using CAPD as the dialysis method even
if some totally blind patients can handle the technique very well
[15, 17].
Clinical symptoms of peripheral neuropathy are frequently
observed in uremic diabetic patients. Walking impairment was
present at the start of dialysis in 66% of our patients. A rapid
improvement of clinical symptoms during the first months
following the start of CAPD was observed in half of them, but
clinical aggravation perhaps of vascular origin, was also en-
countered despite so-called "adequate dialysis."
Severe peripheral vascular disease leading to gangrene and
amputation of the extremities is a common complication in IDD
patients with ESRD. Continuous dialysis has been considered a
contributing factor to the acceleration of peripheral vascular
disease [33]. Until this study this factor has not been observed
in our patients.
Good control of blood glucose can be obtained in IDD
patients on CAPD. First introduced by Flynn [30], the adminis-
tration of insulin into the peritoneal cavity is now widely used
[15, 34, 35]. This route of administration is more physiological,
since the insulin is absorbed mainly through portal circulation.
Many dialysis units recommend adding insulin to the dialysate
Table 3. Evolution of visual function in 15 IDD treated for at least 6
months by CAPD
Table 4. Evolution of peripheral neuropathy in 24 IDD patients
treated by CAPD
Mean nerve conduction
velocity
rn/sec 34.6 4.2 33.8 5.6 34 4 32.7 5
Not measurable, N 9 7 4 2
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bags. Such a techniquc favors the binding of insulin to the
surface of PVC containers [35]. We prefer the direct administra-
tion of insulin through the catheter [36]. The effectiveness of
this procedure in improving glucose control and the advantages
of the injection into an empty pcritoneal cavity, on a long-term
period, are under investigation in our department.
Peritonitis remains the most serious technical complication of
CAPD and can be fatal. The incidence of peritonitis in our
series was one episode per 12.2 patient/months, that is lower
than in our nondiabetic population [12]. The traditional good
training of diabetic patients in the careful handling of aseptic
precautions may explain such satisfactory results achieved
even with blind patients.
In IDD patients, although peritoneal protein losses are similar
to those observed in nondiahetic patients [11, 12, 371, a particu-
lar attention should be paid to malnutrition, the onset of which
can be quite insidious. Anorexia is commonly underestimated.
In our experience, serum albumin levels are a good index of the
nutritional status and should be routinely determined.
The results of kidney replacement treatment in IDD patients
with the exception of living donor kidney transplantation [25,
26] have been inferior to those achieved in a nondiabetic
population of the same age range. According to some authors,
transplantation is a better alternative than dialysis [2, 171.
However, even if kidney transplantation is offered as treatment
of first choice to diabetic patients with ESRD, the shortage of
cadaver kidneys is and will remain for many years, a limiting
factor. On the other hand, transplantation of a kidney from
relatives raises many ethical problems in many countries. We
think that for many years to come the bulk of diabetic patients
with ESRD will rely on dialysis methods for treatment.
The long-term success of CAPD as treatment of ESRI) in
IDD patients will rely on the evidence of a better control of
glucose metabolism than other dialysis methods, on the perma-
nence of an adequate ultrafiltration rate, and on the mainte-
nance of a good nutritional status for many years. Until they
become available, an integrated CAPD-transplantation program
is likely [38] to represent a good strategy of treatment for the
younger age group, and CAPD should be offered as a routine
mode of therapy for older diabetic patients in whom home
dialysis seems indicated. Nevertheless, many patients with
impaired sight will never handle the technique adequately, and
we do not think that the burden of the daily exchange should be
imposed on the relatives. In such circumstances, either CCPD
or IPD can be an adequate alternative.
Summary. From August 1978 to December 1981, 24 insulin-
dependent diabetic (IDD) patients with endstage renal disease
(ESRD) were treated by continuous ambulatory peritoneal
dialysis (CAPD). The average time on CAPD was 10.6 months
(range, 2 to 32 months). At 1 year the actuarial survival rate was
84%, and the rate of continuation on ambulatory peritoneal
dialysis was 75%. We observed six deaths and three transfers to
hemodialysis. The incidence of peritonitis (one episode per 12.2
patient/months) was lower than that in our nondiahetie popula-
tion. The instillation of insulin into the peritoneal cavity was
made through the catheter. Mean residual renal ereatinine
clearance, around 3 ml/min, and the mean peritoneal creatinine
clearance, around 4 mI/mm, remained stable during the obser-
vation. The daily use of no more than 2 liters of dialysate with
4.5% dextrose may prevent major serum lipid abnormalities.
Hypertension was easily controlled in most patients but postur-
al hypotension was also observed. Stabilization or improve-
ment of retinopathy was observed in 12 out of 15 patients
followed for at least 6 months. IDD patients should be offered
all modes of replacement therapy, within an integrated program
of treatment of ESRD. For some, CAPD may be the best
alternative.
Acknowledgments
Portions of this study were supported by a grant from the Association
pour l'Utilisation du Rein Artificiel. We thank Dr. 1). Oreopoulos for
helpful suggestions during the preparation of the manuscript and Mrs.
C. Debrun for secretarial assistance.
Reprint requests to Prof. M. Legrain, Service de Néphrologie,
Groape Hospitalier Pitie Salpetriere, 83 bd de l'Hdpital 74561 Paris
Cedex, France
References
1. Jcons C, BROYER M, BRUNNER FB, BRYNGER H,
DONCICERwOcKE RA, KRAMER P, SELw000 NH, WING AJ: Com-
bined report on regular dialysis and transplantation in Europe. Proc
Fur Dial Transplant Assoc 18:4—57, 1981
2. McCstsav RF, PITT5 TO, PUSCHETT JB: Diabetic nephropathy:
Natural course, survivorship and therapy. Am J Nephrol 1:206—
218, 1981
3. Lscoas C, ROTTEMBOURG J. FRANTz P, SLAMA U, LEGRAIN M:
Ireatment of end stage renal failure in the insulin-dependent
diabetic patient, in Advances in Nephrology, edited by HAMBURG-
ER J, CRO5NIER J, MAXWELL MI-I. Chicago, Yearbook Medical
Publishers, Inc., 1979, vol. 8, pp. 101—126
4. AciicsrloTts A, ROTTEMBOURG J, BALDUCCI A, LEGRAIN M:
Continuous ambulatory peritoneal dialysis in 49 high risk patients.
Thirty month experience, in abst Proc Vilith mt Congr Nephrol,
Athens, 1981, p. 442
5. LEGRAIN M, EL SHAHAT Y, ROTTEMBOURG J, Btoucci A,
JACOBS C: Continuous ambulatory peritoneal dialysis (CAPD)
versus other treatment modalities in end stage diabetic nephrop-
athy, in Advances in Peritoneal Dialysis, edited by GAUL 0,
KE55EL M, NOLPH K. Amsterdam Excerpta Medica, 1981, pp. 365—
368
6. QUELLHOR5T E, SHUENEMANN B, MIETz5CH H: Influence of
different modes of treatment on the complication of diabetes
mellitus, in Advances in Peritoneal Dialysis, edited by GAUL 0,
KE55EL M, NOLPH K. Amsterdam, Excerpta Medica, 1981, pp.
371—375
7. CHAN MK, CHUAU P, RAFTERY MJ, BAILLOD RA, QwENY P,
VARGHESE Z, MOORHEAD IF: Three years' experience of continu-
ous ambulatory peritoneal dialysis, Lancet 1:1409—1412, 1981
8. KUANNA R, OREopouLos DO, D0MBR05 N, VA5 S, WILLIAMS P,
MEEMA HE, JUSDAN H, OGILvIE R, ZELLERMAN U, RONCARDI D,
CLAYTON 5, IzATT 5: Continuous ambulatory peritoneal dialysis
after three years: Still a promising treatment. Peritoneal Dialysis
Bulletin 1:24—34, 1981
9. NOLPH K, SORKIN M, RUBIN J, ARFANIA D, PROWANT B, FRUTO
L, KENNEDY D: Continuous ambulatory peritoneal dialysis: Three
year experience at one center. Ann Intern Med 92:610—613, 1980
10. MONCRIEF JW: Continuous ambulatory peritoneal dialysis. Neph-
ron 27:221—228, 1981
it. OREOPOULOS DG, KIIANNA F, DoMaRos N: Progress in peritoneal
dialysis, in Proc Vilith mt Congr Nephrol, Athens. 1981, pp. 715—
722
12. ROTTEMBOURG J, JAcQ D, KROURI A, MONTEIRO A, GUEFFAF B:
La dialyse peritondale continue ambutatoire: III. Résultats clini-
ques. Nouv Presse Med 9:3158—3163, 1980
13. FLYNN CT: Continuous ambulatory peritoneal dialysis in diabetic
patients, in Continuous Ambulatory Peritoneal Dialysis, edited by
LEGRAIN M. Amsterdam, Excerpta Medica, 1980, pp. 187—193
14. KLIGER AS: Current concepts in peritoneal dialysis. Nephron
27:209—214, 1981
Continuous ambulatory peritoneal dialysis in diabetes 45
15. KATIRZOGLOU A, IZATT S, OREoPouLos D, DOMBROS N, BLAIR G,
CHISHOLM L, MEEMA H, OGILVIE R, VAS S, LIEBEL B,
MCCREEDY W: Chronic peritoneal dialysis in diabetics with end
stage renal failure, in The Diabetic Renal Retinal Syndrome, edited
by L'ESPERANCE F, FRIEDMAN E. New York. Grune & Stratton,
1980, pp. 317—331
16. SLINGENEYER A, MI0N C, SELAM JL: Home intermittent (IPD) and
continuous ambulatory peritoneal dialysis (CAPD) as a long term
treatment of end stage renal failure in diabetics, in Advances in
Peritoneal Dialysis, edited by GAuL G, KESSEL M, NOLPH K.
Amsterdam, Excerpta Medica, 1981, pp. 378—388
17. THOMSON NM, SIMPSON RW, HOOKE D, ATKINS PC: Peritoneal
dialysis in the treatment of diabetic end stage renal failure, in
Peritoneal Dialysis, edited by ATKINS RC, THOMSON NM, FAR-
RELL PC. New York, Churchill Livingstone, 1981, pp. 345—355
18. AMAIR P KI-IANNA R, LEIBEL B, PIERRATOS A, VAS 5, MEEMA E
BLAIR G, CHISI-IOLM L, VAS M, ZINGG W, DIBENI5 G,
OREoPouLos D: Continuous ambulatory peritoneal dialysis in
diabetics with end-stage renal disease. N Engi J Med 306:625—630,
1982
19. ROTTEMBOURG J, JACQ D, VONLANTHEN M, ISSAD B, EL SHAHAT
Y: Straight or curled Tenchkhoff peritoneal catheter for continuous
ambulatory peritoneal dialysis. Peritoneal Dialysis Bulletin 1:123—
124, 1981
20. RENAUX C, CERTAIN B, MOLLET M, ROTTEMBOURG J: La dialyse
péritonéale continue ambulatoire: II. Materiel, technique, forma-
tion. Nouv Presse Med 9:3154—3157, 1980
21. GHAVANIAN M, GUTCH CF. Ko KF, KOLFF WJ: The sad truth
about hemodialysis in diabetic nephropathy. JAMA 222:1386—1389,
1972
22. HOSTEN A, CRUZ IA, RAO MS: Dialysis in diabetic patients with
chronic renal failure. Dialysis Transplant 10:206—209, 1981
23. EL SHAHAT Y, ROTTEMBOURG J, JACOBS C, LEGRAIN M: Le
traitement de l'insuffisance rénale terminale chez les diabetiques
insulino-dependants par les méthodes de dialyse, in 8e Séminaires
d'Uro-Nephrologie Pitié-Salpétrière, edited by Kuss R, LEGRAIN
M, Paris, Masson, 1982, pp. 222—228
24. BRYNGER H, LARSSON 0: 10 years experience of renal transplanta-
tion in diabetic patients, in 8e Séminaires d' Uro-Nephrologie Pitié-
Salpétrière, edited by Kuss R, LEGRAIN M. Paris, Masson, 1982,
pp. 127—138
25. NAJARIAN JS, SUTHERLAND DER, SIMMONS RL, HOWARD R,
KJELLSTRAND C, RAMSAY R, GOETZ F, FRYD D, SOMMER B: Ten
years experience with renal transplantation in juvenile onset diabet-
ics. Ann Surg 190:487—500, 1975
26. ARMSTRONG VW, FUCHS C, SCHELER F: Effect of dialysate glucose
load on plasma glucose and insulin levels in CAPD patients, in
Advances in Peritoneal Dialysis, edited by GAHL G, KESSEL M,
NOLPH K. Amsterdam, Excerpta Medica, 1981, pp. 421—423
27. TURGAN C, FEEHALLY J, BENNETT J, DAVIES TJ, WALLS J: Effect
of continuous ambulatory peritoneal dialysis (CAPD) on lipid
metabolism, inAdvances in Peritoneal Dialysis, edited by GAHL G,
KESSEL M, NOLPH K. Amsterdam, Excerpta Medica, 1981, pp.
417—420
28. LAMEIRE N, RINGOIR S: An overview of peritonitis and other
complications of continuous ambulatory peritoneal dialysis, in
Continuous Ambulatory Peritoneal Dialysis, edited by LEGRAIN M.
Amsterdam, Excerpta Medica, 1980, pp. 229—237
29. FALLER B, MARICHAL iF: Loss of ultrafiltration in continuous
ambulatory peritoneal dialysis, in Advances in Peritoneal Dialysis,
edited by GAHL G, KESSEL M, NOLPH K. Amsterdam, Excerpta
Medica, 1981, pp. 227—232
30. FLYNN CT: Diabetic control by CAPD, in Diabetic Renal Retinal
Syndrome, edited by L'ESPERANCE F, FRIEDMAN EA. New York,
Grune & Stratton, 1979, pp. 435—438
31. EL SHAHAT Y, ROTTEMBOURG J, BELLIO P, GUIMONT MC,
ROUSSELIE F, JACOBS C: Visual function can be preserved in insulin
dependent diabetic patients treated by maintenance hemodialysis.
Proc Europ Dial Transplant Assoc 17:167—172, 1982
32. STENO STUDY GROUP: Effect of 6 months of strict metabolic
control on eye and kidney function in insulin dependent diabetics
with background retinopathy. Lancet 1:121—123, 1982
33. BROWN PM, JOHNSTON KW, FENTON SSA, CATTRAN DC: Symp-
tomatic exacerbation of peripheral vascular diseases with chronic
ambulatory peritoneal dialysis. Clin Nephrol 16:258—261, 1981
34. GREENWOOD RH, DAVIES CJ, SENATOR GB, O'BRIEN I, HAYES
TM: Intraperitoneal insulin in diabetics (letter). Lancet 2:312, 1979
35. WIDEROE T-E, SMEBY LC, BERG KJ, JOPSTAG 5, SVARTAS TM:
Intraperitoneal (125J) insulin absorption during intermittent and
continuous peritoneal dialysis, in Advances in Peritoneal Dialysis,
edited by GAHL G, KESSEL M, NOLPH K. Amsterdam, Excerpta
Medica, 1981, pp. 369—370
36. BALDUCCI A, SLAMA G, ROTTEMBOURG J, BAUMELOU A, DELAGE
A: Intraperitoneal insulin in uraemic diabetics undergoing continu-
ous ambulatory peritoneal dialysis. Br MedJ 283:1021—1023, 1981
37. BLUMENKRANTZ Mi, KOPPLE JD, MORAN JK, BRODSTEIN GP,
COBURN JW: Nitrogen and urea metabolism during continuous
ambulatory peritoneal dialysis. Kidney mt 20:78—82, 1981
38. BOEN F: Integration of continuous ambulatory peritoneal dialysis
into end stage renal failure programme: Present and future, in
Peritoneal Dialysis, edited by ATKINS R, THOMSON N, FARRELL P.
London, Churchill, 1981, pp. 424—429
